Kaplan-Meier survival curves of 214 myeloma patients included in the HOVON-50/54 studies by treatment according to protocol initiated after auto-SCT. Actuarial rates of PFS2 (A) and OS2 (B) according to treatment started after auto-SCT, ie, allo-RIC versus maintenance with thalidomide or α-interferon (including 3 patients who received a second HDM-200). PFS2 and OS2 are presented as from the date of allo-RIC or second HDM, or start maintenance, whichever applicable.